VRXA · Company research
Veraxa Biotech AG (VRXA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| One dose of VERAXA's two-part cancer treatment shrank tumors in a breast cancer model - Stock Titan | One dose of VERAXA's two-part cancer treatment shrank tumors in a breast cancer model Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy | VERAXA Biotech announced its implementation of FDA-aligned New Approach Methodologies (NAMs) across its preclinical R&D programs to accelerate its BiTAC oncology pipeline while significantly reducing animal testing. The company presented data showing its BiTAC-TCE candidates demonstrated superior safety profiles and matched efficacy compared to traditional T cell engagers, with ex vivo studies using patient-derived xenograft models requiring only 10 mice versus 200+ for traditional studies. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy | VERAXA Biotech announced its implementation of FDA-aligned New Approach Methodologies (NAMs) across its preclinical R&D programs to accelerate its BiTAC oncology pipeline while significantly reducing animal testing. The company presented data showing its BiTAC-TCE candidates demonstrated superior safety profiles and matched efficacy compared to traditional T cell engagers, with ex vivo studies using patient-derived xenograft models requiring only 10 mice versus 200+ for traditional studies. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| Veraxa Biotech AG (VRXA) Stock Price & News - Syfe | Veraxa Biotech AG (VRXA) Stock Price & News Syfe | View source ↗ | Syfe | Sep 30, 2026 | neutral | 0 | 0.6 |
| VRXA Should I Buy - Intellectia AI | VRXA Should I Buy Intellectia AI | View source ↗ | Intellectia AI | Sep 26, 2026 | neutral | 0 | 0.6 |
| Veraxa Biotech AG (VRXA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade | Veraxa Biotech AG (VRXA) Stock Price | Live Quotes & Charts | NASDAQ StocksToTrade | View source ↗ | StocksToTrade | Sep 25, 2026 | neutral | 0 | 0.6 |
| $VRXA stock is up 15% today. Here's what we see in our data. - Quiver Quantitative | $VRXA stock is up 15% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 4, 2026 | neutral | 0 | 0.6 |
| Veraxa Biotech (VRXA) Stock Chart and Price History 2026 - MarketBeat | Veraxa Biotech (VRXA) Stock Chart and Price History 2026 MarketBeat | View source ↗ | MarketBeat | Sep 1, 2026 | neutral | 0 | 0.6 |
| VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase - Benzinga | VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase Benzinga | View source ↗ | Benzinga | Aug 25, 2026 | neutral | 0 | 0.6 |
| Veraxa Biotech (VRXA) Stock Price, News & Analysis - Stock Titan | Veraxa Biotech (VRXA) Stock Price, News & Analysis Stock Titan | View source ↗ | Stock Titan | Jul 2, 2026 | neutral | 0 | 0.6 |
| Veraxa Biotech Stock: Post-Merger Valuation Does Not Match The Risk (NASDAQ:VRXA) - Seeking Alpha | Veraxa Biotech Stock: Post-Merger Valuation Does Not Match The Risk (NASDAQ:VRXA) Seeking Alpha | View source ↗ | Seeking Alpha | Jun 17, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Jun 12, 2026 | neutral | 0 | 0.6 |
| Veraxa Biotech (Nasdaq:VRXA) - Stock Analysis - Simply Wall Street | Veraxa Biotech (Nasdaq:VRXA) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Jun 12, 2026 | neutral | 0 | 0.6 |
| Veraxa Biotech AG Ordinary Shares (VRXA) Historical Quotes - Nasdaq | Veraxa Biotech AG Ordinary Shares (VRXA) Historical Quotes Nasdaq | View source ↗ | Nasdaq | Jun 11, 2026 | neutral | 0 | 0.6 |
| Veraxa Biotech AG (VRXA) stock price, news, quote and history - Yahoo Finance UK | Veraxa Biotech AG (VRXA) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Jun 10, 2026 | neutral | 0 | 0.6 |
| Veraxa Biotech AG (VRXA) Stock Price, News, Quote & History - Yahoo! Finance Canada | Veraxa Biotech AG (VRXA) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Jun 9, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.